Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading 89bio Inc chart...

About the Company

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.

Exchange

NASDAQ

Website

89bio.com

$M

Total Revenue

45

Employees

$1B

Market Capitalization

-6.63

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ETNB News

89bio Inc

23d ago, source: CNN

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.

Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come

on MSN ago, source:

A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca ...

89bio Inc Ordinary Shares

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10d ago, source:

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical ...

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

18d ago, source: Business Insider

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic ...

Madrigal’s stock surges as FDA approves first drug for liver disease MASH

on MSN ago, source:

Madrigal Pharmaceuticals on Thursday received the FDA’s first approval of a drug designed to treat a severe liver disease ...

89bio to Participate in the Leerink Partners Global Biopharma Conference

13d ago, source: Nasdaq

SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies ...

89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ...

17d ago, source: Yahoo Finance

Warning! GuruFocus has detected 2 Warning Sign with ETNB. On February 29, 2024, 89bio Inc (NASDAQ:ETNB) released its 8-K filing, detailing the financial results for the fourth quarter and full ...

13 Best Biotech Stocks To Buy Under $20

5d ago, source:

At just $1.38 per share, Gossamer Bio Inc (NASDAQ:GOSS) is the least expensive in the list of best biotech stocks to buy ...

89bio Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

89bio, Inc.: 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10d ago, source: Finanznachrichten

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...